Homozygous Familial Hypercholesterolemia (HoFH) – Global Clinical Trials Review, H2, 2021

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

GlobalData’s clinical trial report provides an overview of the homozygous familial hypercholesterolemia (hofh) clinical trials scenario. This report provides top-line data relating to the clinical trials on homozygous familial hypercholesterolemia. The report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on the number of ongoing trials). The report enhances the decision-making capabilities and helps to create effective counterstrategies to gain a competitive advantage.

The homozygous familial hypercholesterolemia (hofh) clinical trial report consists of 419 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 14, 32, 29, 319, and 2 respectively. Similarly, the trials with different status compile of Completed – 306, Ongoing – 30, Planned – 40, Suspended – 1, Terminated – 5, and Withdrawn – 37. Out of 306 completed trials 203 trials have achieved endpoint.

What are the market dynamics of the global homozygous familial hypercholesterolemia therapeutics clinical trials sector?

The number of homozygous familial hypercholesterolemia clinical trials conducted globally has increased by 93% for the period 2016-2020. The average number of patients enrolled was highest in the year 2016. Out of the total clinical trials conducted, over 90% of trials have been sponsored by the company and more than 5% by institutions. As of November 2021, there were 30 clinical trials in progress and 306 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 43. This was due to the lack of efficacy, safety, and lack of accrual of subjects. Out of 306 completed trials, 212 trials have results and 203 (96%) of trials reached endpoints.

What are the top regions and countries in the global homozygous familial hypercholesterolemia therapeutics clinical trials sector?

In total there were 419 clinical trials conducted on homozygous familial hypercholesterolemia, as of November 2021, of these 138 clinical trials were in Asia-Pacific. More than 30% of the clinical trials were conducted in Asia-Pacific. During the same period, Germany has the highest average patient enrollment of homozygous familial hypercholesterolemia clinical trials.

Asia-Pacific: In the Asia-Pacific region, China has the highest number of homozygous familial hypercholesterolemia clinical trials, as of November 2021, followed by Thailand, Japan, South Korea, and India.

Europe: Among the European countries, Russia has the highest number of homozygous familial hypercholesterolemia clinical trials, as of November 2021, followed by the Netherlands, Italy, Germany, and France.

North America: In the country-wise analysis, the US has the highest number of homozygous familial hypercholesterolemia clinical trials, as of November 2021, followed by Canada, and Mexico.

The Middle East and Africa: South Africa has the highest number of homozygous familial hypercholesterolemia (hofh) clinical trials followed by Israel, Lebanon, Iran, and Jordan which are the leading countries in the region based on homozygous familial hypercholesterolemia clinical trials.

Central and South America: Brazil has the highest number of homozygous familial hypercholesterolemia clinical trials in the region followed by Argentina and Colombia.

G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, Canada has the highest proportion of Homozygous familial hypercholesterolemia to metabolic disorders clinical trials as of November 2021. In total there were 159 clinical trials conducted on homozygous familial hypercholesterolemia, as of November 2021 in G7 Countries, of these 51 clinical trials were in the US. During the same period, there were 13 clinical trials in progress and 58 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 11. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Homozygous familial hypercholesterolemia to metabolic disorders clinical trials as of November 2021. During the same period, in total there were 130 clinical trials conducted on homozygous familial hypercholesterolemia of these 53 clinical trials were in China. There were 20 clinical trials in progress and 76 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 11. As of November 2021, the majority of the trials were successfully completed.

Global homozygous familial hypercholesterolemia therapeutics clinical trials sector, by regions

Global homozygous familial hypercholesterolemia therapeutics clinical trials sector, by regions

For more regional insights, download a free report sample

Which are the key companies in the global homozygous familial hypercholesterolemia therapeutics clinical trials sector?

As of November 2021, Teva Pharmaceutical Industries Ltd has conducted the highest number of homozygous familial hypercholesterolemia clinical trials, followed by Merck & Co Inc, and Amryt Pharma Plc. Other major companies in the sector are Dr. Reddy’s Laboratories Ltd, International Bio Service Co Ltd, Novartis AG, Amgen Inc, Krka dd Novo Mesto, Bio-Innova & Synchron Co Ltd, and Madrigal Pharmaceuticals Inc.

Global homozygous familial hypercholesterolemia therapeutics clinical trials sector, by key companies

Global homozygous familial hypercholesterolemia therapeutics clinical trials sector, by key companies

To know more about key companies, download a free report sample

Market report scope

Key countries

China, the US, Russia, Canada, Thailand, the Netherlands, Japan, Italy, South Korea, and Germany
Key companies Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Amryt Pharma Plc, Dr. Reddy’s Laboratories Ltd, International Bio Service Co Ltd, Novartis AG, Amgen Inc, Krka dd Novo Mesto, Bio-Innova & Synchron Co Ltd, and Madrigal Pharmaceuticals Inc.

 Scope

  • The report provides a snapshot of the global clinical trials landscape.
  • Report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
  • The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
  • The report provides enrollment trends for the past five years.
  • Report provides the latest news for the past three months.

Reasons to Buy

  • Assists in formulating key business strategies with regard to investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrolment trends by country in the global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional, and country level.

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Source

Table

List of Tables

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Region, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, North America, Top Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Central and South America, Top Countries, 2021*

Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Phase 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

Figures

List of Figures

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Region (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, North America, Top Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2021*

Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Phase (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

GlobalData Methodology

Frequently asked questions

Homozygous Familial Hypercholesterolemia (HoFH) – Global Clinical Trials Review, H2, 2021 standard reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Homozygous Familial Hypercholesterolemia (HoFH) – Global Clinical Trials Review, H2, 2021 in real time.

  • Access a live Homozygous Familial Hypercholesterolemia (HoFH) – Global Clinical Trials Review, H2, 2021 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.